ESPE Abstracts

Background: The prevalence of childhood obesity is increasing worldwide and Glucagon-like peptide 1 analogs have emerged as a new tool for its management. To date, Liraglutide has been approved for the treatment of obesity in adolescents over 12 years of age by the FDA & EMEA and in Chile (July 2021).Objectives: evaluate the % decrease in BMI SDS and total body fat percentage in adolescents with obesity who received ...